Related Experiment Video

Updated: Aug 7, 2026

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

Checkpoint-insulated triple-signal artificial antigen-presenting cells drive antigen relay and systemic antitumor

Siyu Zhao1, Tianzi Shi1, Tianyi Tian1

  • 1Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China.

Proceedings of the National Academy of Sciences of the United States of America
|August 5, 2026
PubMed

Insights

A novel artificial antigen-presenting cell (OncoAPC) vaccine integrates tumor antigen presentation with immune activation signals. This approach demonstrates broad therapeutic activity against multiple cancers, outperforming dendritic cell vaccines.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Dendritic cell (DC) vaccines excel at antigen presentation but have limited lymphoid tissue trafficking.
  • Whole tumor cell vaccines offer antigenic diversity but lack T cell activation cues.

Purpose of the Study:

  • To develop and evaluate OncoAPC, an artificial antigen-presenting cell designed for enhanced cancer immunotherapy.
  • To assess the therapeutic efficacy and mechanism of OncoAPC in preclinical cancer models.

Main Methods:

  • OncoAPC was engineered with triple-signal priming logic: MHC-I antigen presentation, CD80 costimulation, and IL-12.
  • Mechanistic studies involved assessing T cell activation, PD-1 suppression insulation, and engagement of endogenous DCs.
  • Therapeutic efficacy was evaluated in multiple tumor models, comparing OncoAPC to conventional DC vaccination.

Main Results:

  • OncoAPC directly activated T cells and partially insulated against PD-1 suppression via CD80:PD-L1 interactions.
  • OncoAPC engaged endogenous DCs through cross-dressing, amplifying lymphoid priming.
  • OncoAPC demonstrated broad therapeutic activity, suppressing metastatic tumor burden and controlling established tumors, outperforming DC vaccines.

Conclusions:

  • OncoAPC represents a scalable cancer vaccine platform integrating antigenic diversity with DC-like precision.
  • The artificial antigen-presenting cell platform shows promise for broad-spectrum cancer immunotherapy.
  • OncoAPC maintains efficacy across different tumor types and generation methods.
Keywords:
antigen cross-dressingartificial antigen-presenting cellscis CD80:PD-L1 complexescolorectal cancerimmunotherapy

More Related Videos

Artificial Antigen Presenting Cell (aAPC) Mediated Activation and Expansion of Natural Killer T Cells13:18

Artificial Antigen Presenting Cell (aAPC) Mediated Activation and Expansion of Natural Killer T Cells

Published on: December 29, 2012

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants10:44

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

Related Concept Videos

Antigen Presenting Cells01:22

Antigen Presenting Cells

The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Vaccinations01:51

Vaccinations

Overview